Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects
Public ClinicalTrials.gov record NCT04334460. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Antiviral Activity of BLD-2660 in Hospitalized Subjects With Recently Diagnosed COVID-19 Compared to Standard of Care Treatment
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, and 9 that is selective over the cathepsins as well as other protease families, displays good metabolic stability and permeability, oral bioavailability and low cytochrome P450 (CYP) inhibition. It is under development for the treatment of coronavirus disease-19 (COVID-19) resulting from infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV2), where there is significant unmet medical need.
Study identification
- NCT ID
- NCT04334460
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 120 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 3, 2020
- Primary completion
- Nov 10, 2020
- Completion
- Jun 20, 2021
- Last update posted
- Apr 5, 2022
2020 – 2021
United States locations
- U.S. sites
- 27
- U.S. states
- 17
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Blade Research Site | Irvine | California | 92697 | — |
| Blade Research Site | Los Angeles | California | 90048 | — |
| Blade Reseach Site | San Jose | California | 95128 | — |
| Blade Research Site | Washington D.C. | District of Columbia | 20007 | — |
| Blade Research Site | Washington D.C. | District of Columbia | 20010 | — |
| Blade Research Site | Brandon | Florida | 33511 | — |
| Blade Research Site | Ft. Pierce | Florida | 34982 | — |
| Blade Research Site | Panama City | Florida | 32405 | — |
| Blade Research Site | Tampa | Florida | 33620 | — |
| Blade Research Site | Idaho Falls | Idaho | 83404 | — |
| Blade Research Site | Peoria | Illinois | 61603 | — |
| Blade Research Site | Ames | Iowa | 50010 | — |
| Blade Research Site | Lexington | Kentucky | 40503 | — |
| Blade Research Site | Louisville | Kentucky | 40207 | — |
| Blade Research Site | Baltimore | Maryland | 21201 | — |
| Blade Research Site | Detroit | Michigan | 48202 | — |
| Blade Research Site | Farmington Hills | Michigan | 48334 | — |
| Blade Research Site | Omaha | Nebraska | 68114 | — |
| Blade Research Site | Ridgewood | New Jersey | 07450 | — |
| Blade Research Site | Charleston | North Carolina | 29414 | — |
| Blade Research Site | Durham | North Carolina | 27708 | — |
| Blade Research Site | Fayetteville | North Carolina | 28304 | — |
| Blade Research Site | Philadelphia | Pennsylvania | 19140 | — |
| Blade Research Site | Charleston | South Carolina | 29414 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37203 | — |
| Blade Research Site | Dallas | Texas | 75203 | — |
| Blade Research Site | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04334460, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 5, 2022 · Synced Sep 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04334460 live on ClinicalTrials.gov.